Influenza B IgM ELISA kit is an enzyme immunoassays (microtiter strips) for the qualitative and quantitative determination of IgM antibodies against Influenza B virus (strain Beijing and Sydney) in human serum and plasma. Influenza B IgM ELISA kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The wells of this Influenza B IgM ELISA kit are coated with antigen. Specific antibodies of the sample binding to the antigen coated wells are detected by a secondary enzyme conjugated antibody (E-Ab) specific for human IgM. After the substrate reaction the intensity of the color developed is proportional to the amount of IgA-specific antibodies detected. Results of samples can be determined directly using the standard curve.
The Influenza B IgM ELISA kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sunlight. The storage and stability of specimen and prepared reagents is stated in the protocol insert. The microtiter strips of this Influenza B IgM ELISA kit are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.
The test results obtained using this Influenza B IgM ELISA kit are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards used with this Influenza B IgM ELISA kit must be found within the acceptable ranges as stated on the QC Certificate. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls. In case of any deviation the following technical issues should be proven: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods. It is recommended to participate at appropriate quality assessment trials.
The influenza infection is an acute feverish virus infection of the respiratory tract. The infection mostly results from a droplet infection and appears as an epidemic or pandemy. The virus and its toxin can lead to a serious inflammation of the bronchial mucosa and a damage of the vessels. After an incubation time of 1 to 3 days the symptoms appear suddenly: Followed by a fast raise of temperature, often accompanied by shivering, the leading symptom of catarrhal inflammation appears, contributing to the clinical course of painful dry cough, tracheitis, laryngitis and frequently a rhinitis and conjunctivitis. The determination of the Influenza type (A, B, and C) gives both the clinician and epidemiologist important indications for further actions. Thus Influenza B often leads to a serious clinical course and an epidemic spread of the virus. Similarly, during an Influenza A epidemic, the epidemiological importance and derived measurements of the protection of the individual are important.
Download Product Data Sheet